Claims for Patent: 10,967,077

Summary for Patent: 10,967,077

Title:	Imaging of metastatic or recurrent cancer
Abstract:	The present disclosure relates to methods of administering [.sup.18F]-FACBC. The present disclosure also relates to use of [.sup.18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s):	Miller; Matthew (Oxford, GB), Gauden; David (Oxford, GB), Schuster; David (Atlanta, GA), Fanti; Stefano (Bologna, IT), Nanni; Cristina (Bologna, IT), Zanoni; Lucia (Bologna, IT), Willoch; Frode (Oslo, NO), Bogsrud; Trond Velde (Oslo, NO), Bach-Gansmo; Tore (Oslo, NO), Musto; Alessandra (Bologna, IT)
Assignee:	Blue Earth Diagnostics Limited (Oxford, GB)
Application Number:	16/907,863
Patent Claims:	1. A method of using anti-1-amino-3-.sup.18F-fluorocyclobutane-1-carboxylic acid ([.sup.18F]-FACBC), comprising: a) administering the [.sup.18F]-FACBC in a dose of 370 MBq as an intravenous bolus injection into a human subject having a suspected prostate cancer recurrence, wherein the [.sup.18F]-FACBC injection is followed by an intravenous flush; and b) acquiring a positron emission tomography (PET) scan image of the human subject during a PET scan; wherein the human subject has: i. consumed no food or drink including water for at least 4 hours prior to the injection, except sips of water for taking medications, and ii. avoided significant exercise for at least one day prior to the PET scan; wherein the human subject is positioned in a supine position with arms above the head before the PET scan starts; wherein the PET scan starts 3 to 5 minutes after the end of the [.sup.18F]-FACBC injection; and wherein the PET scan starts from at least the human subject's proximal thigh and proceeds to the base of the human subject's skull for a total scan time of up to 30 minutes. 2. The method of claim 1, further comprising analysing the PET scan image for a small lesion less than 1 cm at a suspicious location, and identifying the lesion as suspicious for the prostate cancer recurrence if an uptake of [.sup.18F]-FACBC by the lesion is greater than blood pool.